SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001839882-23-004980
Filing Date
2023-02-27
Accepted
2023-02-27 16:35:42
Documents
15
Period of Report
2023-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT admp-8k_022423.htm   iXBRL 8-K 59011
2 AGREEMENT AND PLAN OF REORGANIZATION ex2-1.htm EX-2.1 663995
3 FORM OF SUPPORT AGREEMENT ex10-1.htm EX-10.1 109319
4 PRESS RELEASE ex99-1.htm EX-99.1 29091
  Complete submission text file 0001839882-23-004980.txt   1214320

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT admp-20230224.xsd EX-101.SCH 3266
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT admp-20230224_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT admp-20230224_pre.xml EX-101.PRE 22385
9 EXTRACTED XBRL INSTANCE DOCUMENT admp-8k_022423_htm.xml XML 3588
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36242 | Film No.: 23675582
SIC: 2834 Pharmaceutical Preparations